Analysis of laboratory parameters in patients with covid-19: Experiences from a pandemic hospital

Aim: This study aimed to determine the analysis of the laboratory parameters in patients infected with SARS-CoV-2 during the early pandemic period in Turkey. Material and Methods: This retrospective descriptive study was conducted at a pandemic hospital. All hospitalized patients and outpatients with a positive RT-PCR assay for SARS-CoV-2 were included in the study. Demographics, clinical characteristics, vital parameters on admission, laboratory findings, and drugs used for SARS-CoV-2 infection were obtained from the computer-based patient data system of the hospital and analyzed. The primary outcome of the study was the laboratory parameters of patients with COVID-19. The secondary outcome was 30-day all-cause mortality following emergency department admis-sion. Results: A total of 2,012 patients were included in study. The rates of hospitalization and 30-day mortality were 24% and 2%, respectively. The most common symptom was cough, and the most common comorbidity was hypertension. The neutrophil count, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio values were elevated in the non-survivor group compared to the survivor group (P = 0.001, P < 0.001, and P = 0.020, respectively). The lymphocyte and platelet counts were elevated in the survivor group compared to the non-survivor group (P = 0.001 and P < 0.001, respectively). As predictors of mortality, the cut-off value for the neutrophil, lymphocyte and platelet counts, and the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios were 5.68, 1.42, 195, 3.09, and 141.8, respectively, and the AUC was determined as 0.704, 0.714, 0.727, 0.745, and 0.610, respectively (P < 0.001, P < 0.001, P < 0.001, P < 0.001, and P = 0.023, respectively). Discussion: The results of the study demonstrated that the neutrophil count, lymphocyte count, platelet count, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are useful in determining prognosis in SARS-CoV-2 infection.